My watch list
my.bionity.com  
Login  

10 Newest Publications

rss

A contrast in safety, pharmacokinetics, and pharmacodynamics across age groups after a single 50‐mg oral dose of the γ‐secretase inhibitor avagacestat

23-05-2012 | Gary Tong, Jun‐Sheng Wang, Oleksandr Sverdlov, Shu‐Pang Huang, Randy Slemmon, Robert Croop, Lorna Castaneda, Huidong ..., British Journal of Clinical Pharmacology, 2012

, especially in the target population of elderly subjects with mild cognitive impairment or Alzheimer's disease © 2012 Bristol‐Myers Squibb. British Journal of Clinical Pharmacology © 2012 The British...

more

Downstream reactions and engineering in the microbially reconstituted pathway for Taxol

30-03-2012 | Ming Jiang, Gregory Stephanopoulos, Blaine A. Pfeifer, Applied Microbiology and Biotechnology, 2012

Taxol (a trademarked product of Bristol-Myers Squibb) is a complex isoprenoid natural product which has displayed potent anticancer activity. Originally isolated from the Pacific yew tree (Taxus...

more

Deal watch: Bristol-Myers Squibb invests in cancer antibody that targets the innate immune system

31-08-2011 | Nature Reviews Drug Discovery, 2011

Deal watch: Bristol-Myers Squibb invests in cancer antibody that targets the innate immune system Nature Reviews Drug Discovery 10, 648 (2011). doi:10.1038/nrd3537 Bristol-Myers...

more

Belatacept

31-08-2011 | Flavio Vincenti; Argyris Dritselis; Peter Kirkpatrick, Nature Reviews Drug Discovery, 2011

; Bristol-Myers Squibb), a fusion protein that inhibits T cell activation by binding to CD80 and CD86, was approved by the US Food and Drug Administration (FDA) for the prophylaxis of organ rejection in adult...

more

Ipilimumab

01-06-2011 | Vernon K. Sondak, Keiran S. M. Smalley, Ragini Kudchadkar, Seden Grippon, Peter Kirkpatrick, Nature Reviews Drug Discovery, 2011

Kirkpatrick In March 2011, ipilimumab (Yervoy; Bristol-Myers Squibb), a human monoclonal antibody specific for human cytotoxic T lymphocyte-associated antigen 4 (CTLA4), was approved by the US Food and Drug...

more

Immunotherapy for metastatic melanoma approved

21-04-2011 | Maria Papatriantafyllou, Nature Reviews Immunology, 2011

given hope with the news that ipilimumab (Yervoy; Bristol-Myers Squibb), a monoclonal antibody specific for cytotoxic T lymphocyte antigen 4 (CTLA4), has been approved by the US Food and Drug...

more

Cardiovascular drugs: A determinant of clopidogrel efficacy

01-02-2011 | Charlotte Harrison, Nature Reviews Drug Discovery, 2011

(Plavix; Sanofi-Aventis/Bristol-Myers Squibb) — which is a purinergic P2Y12 receptor antagonist — is widely used for the management of clot-related cardiovascular events. However, there is high inter...

more

The patent cliff steepens

31-12-2010 | Nature Reviews Drug Discovery, 2010

The patent cliff steepens Nature Reviews Drug Discovery 10, 12 (2011). doi:10.1038/nrd3356 Many blockbuster drugs — including Lipitor (atorvastatin; Pfizer), Plavix (clopidogrel; Sanofi–Aventis/Bristol-Myers...

more

Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma

16-11-2010 | Karl S Peggs; Sergio A Quezada, Expert Review of Anticancer Therapy, 2010

the study of Hodi and colleagues evaluating the role of blockade of one of these pathways (cytotoxic T-lymphocyte antigen-4) with a monoclonal antibody (ipilimumab, developed by Medarex, NJ, USA and Bristol-Myers...

more

Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall

05-11-2010 | Emma Dorey, Nature Biotechnology, 2010

Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall Nature Biotechnology 28, 1137 (2010). doi:10.1038/nbt1110-1137 Author: Emma Dorey ...

more

Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE